Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Data from the Centers for Disease Control and Prevention (CDC) indicates that more than 42% of adults in the country are living with obesity, which is creating a large treatment-eligible population for incretin-based therapies
However, eligibility is also extended to individuals with a lower BMI of 27 or greater if they have at least one weight-related health condition
The SURMOUNT trials show consistently greater weight loss with tirzepatide compared to semaglutide, but also steeper regain after discontinuation
By losing weight slowly, you allow your bodys metabolic set point to adjust gradually, which often leads to more sustainable long-term results than a crash diet
Put your utensils down between bites and wait 20 minutes before deciding if you need more food
